“Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1 Antibody, in Patients With Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-up Efficacy and Safety Data”. SKIN The Journal of Cutaneous Medicine, vol. 3, no. 2, Mar. 2019, p. 169, https://doi.org/10.25251/skin.3.2.9.